ImmunityBio (IBRX) Net Income towards Common Stockholders Growth (3y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -10.84% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 26.38% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -46.86% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 13.80% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 34.98% |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -3.84% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 47.10% |
| 10 | ImmunityBio | 7.72 Bn | 7.34 Bn | 43.97 Mn | -75.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -75.74% |
| Dec 31, 2025 | 16.99% |
| Sep 30, 2025 | 15.41% |
| Jun 30, 2025 | 0.79% |
| Mar 31, 2025 | -7.99% |
| Dec 31, 2024 | 13.54% |
| Sep 30, 2024 | 1.02% |
| Jun 30, 2024 | -14.62% |
| Mar 31, 2024 | -18.56% |
| Dec 31, 2023 | -50.43% |
| Sep 30, 2023 | -13.07% |
| Jun 30, 2023 | -38.51% |
| Mar 31, 2023 | -46.04% |
| Dec 31, 2022 | 0.51% |
| Sep 30, 2022 | -92.51% |
| Jun 30, 2022 | -78.47% |
| Mar 31, 2022 | -79.24% |
| Dec 31, 2021 | -47.29% |
| Sep 30, 2021 | -55.24% |
| Jun 30, 2021 | -47.72% |
| Mar 31, 2021 | -43.01% |
| Dec 31, 2020 | -40.95% |
| Sep 30, 2020 | -40.28% |
| Jun 30, 2020 | -30.41% |
| Mar 31, 2020 | -15.15% |
| Dec 31, 2019 | -65.57% |
| Sep 30, 2019 | 21.24% |
| Jun 30, 2019 | 21.13% |
| Mar 31, 2019 | 16.46% |
| Dec 31, 2018 | -28.40% |
| Sep 30, 2018 | 20.09% |
| Jun 30, 2018 | 40.39% |
| Mar 31, 2018 | 5.73% |
| Dec 31, 2017 | -107.65% |
| Sep 30, 2017 | -199.08% |
| Jun 30, 2017 | -156.11% |
| Mar 31, 2017 | -209.61% |